China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal
29/05/2026 24:15
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal May 29 (Reuters) - Chinese biopharmaceutical firm Innovent Biologics 1801.HK and U.S. pharma giant Pfizer have struck a global licensing and collaboration deal worth up to $10.5 billion to research and develop 12 early-stage cancer medicines, the companies said on Friday.
(Reporting by Sherin Sunny in Bengaluru; editing by Alan Barona)
Recent news on Pfizer
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials